Nothing Special   »   [go: up one dir, main page]

Kunicki et al., 1998 - Google Patents

The effects of age, apolipoprotein E phenotype and gender on the concentration of amyloid-β (Aβ) 40, Aβ42, apolipoprotein E and transthyretin in human …

Kunicki et al., 1998

Document ID
17692090456716625141
Author
Kunicki S
Richardson J
Mehta P
Kim K
Zorychta E
Publication year
Publication venue
Clinical biochemistry

External Links

Snippet

Objective: To test whether the concentrations of amyloid-β (Aβ) 40, Aβ42, apolipoprotein E (apoE) and transthyretin in the CSF of normal individuals, are linked to three factors which modulate the risk of Alzheimer's disease (AD): chronological age, gender, and the presence …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—G01N2333/4701
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Similar Documents

Publication Publication Date Title
Kunicki et al. The effects of age, apolipoprotein E phenotype and gender on the concentration of amyloid-β (Aβ) 40, Aβ42, apolipoprotein E and transthyretin in human cerebrospinal fluid
US5270165A (en) Method of diagnosis of amyloidoses
Skoog et al. Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds
Blennow et al. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?
Mehta et al. Amyloid β protein 1–40 and 1–42 levels in matched cerebrospinal fluid and plasma from patients with Alzheimer disease
Nilsberth et al. The'Arctic'APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation
US7387879B2 (en) Diagnosis of tauopathies
Sennvik et al. Levels of α-and β-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients
Schupf et al. Elevated plasma amyloid β-peptide 1–42 and onset of dementia in adults with Down syndrome
De Leon et al. MRI and CSF studies in the early diagnosis of Alzheimer's disease
Toledo et al. Plasma amyloid beta measurements-a desired but elusive Alzheimer's disease biomarker
Jäkel et al. Aβ43 in human Alzheimer’s disease: effects of active Aβ42 immunization
Attems et al. Amyloid β peptide 1–42 highly correlates with capillary cerebral amyloid angiopathy and Alzheimer disease pathology
Cho et al. Quantitation of apoE domains in Alzheimer disease brain suggests a role for apoE in Aß aggregation
Andreasen et al. β-Amyloid (Aβ) protein in cerebrospinal fluid as a biomarker for Alzheimer’s disease
Skoog et al. A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele
JPH11511257A (en) Quantitation of p97 for diagnosing and monitoring Alzheimer's disease
Shoji et al. The levels of cerebrospinal fluid Aβ40 and Aβ42 (43) are regulated age-dependently
Merched et al. Cerebrospinal fluid apolipoprotein E level is increased in late-onset Alzheimer's disease
Noelker et al. Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential
Shoji Cerebrospinal fluid Abeta40 and Abeta42: natural course and clinical usefulness
Bornebroek et al. Hereditary cerebral hemorrhage with amyloidosis dutch type (AβPP 693): Decreased plasma amyloid-β 42 concentration
Henriksson et al. Analysis and quantitation of the β‐amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients with a monoclonal antibody‐based immunoassay
US20160178646A1 (en) Methods for detecting amyloid beta amyloidosis
Matsumoto et al. Blood-brain barrier permeability correlates with medial temporal lobe atrophy but not with amyloid-β protein transport across the blood-brain barrier in Alzheimer’s disease